The Hypersomnia drugs in development market research report provides comprehensive information on the therapeutics under development for Hypersomnia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypersomnia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypersomnia and features dormant and discontinued products.
GlobalData tracks 19 drugs in development for Hypersomnia by 16 companies/universities/institutes. The top development phase for Hypersomnia is phase i with five drugs in that stage. The Hypersomnia pipeline has 19 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hypersomnia pipeline products market are: NLS Pharmaceutics, Takeda Pharmaceutical and Jazz Pharmaceuticals.
The key targets in the Hypersomnia pipeline products market include Orexin Receptor Type 2, Sodium Dependent Dopamine Transporter, and Gamma-Aminobutyric Acid Type B Receptor Subunit.
The key mechanisms of action in the Hypersomnia pipeline product include Orexin Receptor Type 2 Agonist with eight drugs in Phase II. The Hypersomnia pipeline products include two routes of administration with the top ROA being Oral and one key molecule types in the Hypersomnia pipeline products market including Small Molecule.
Hypersomnia overview
Hypersomnia is a neurological disorder of excessive time spent sleeping or excessive sleepiness. It can have many possible causes (such as seasonal affective disorder) and can cause distress and problems with functioning. It is a pathological state characterized by a lack of alertness during the waking episodes of the day. The main symptom of hypersomnia is excessive daytime sleepiness (EDS), or prolonged nighttime sleep, which has occurred for at least 3 months prior to diagnosis
For a complete picture of Hypersomnia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
